Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer

BACKGROUND: Targeted therapies, associated with standard chemotherapies, have improved breast cancer care. However, primary and acquired resistances are frequently observed and the development of new concepts is needed. High-throughput approaches to identify new active and safe molecules with or wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezil, Lynda, Berruyer-Pouyet, Carole, Cabaud, Olivier, Josselin, Emmanuelle, Combes, Sébastien, Brunel, Jean-Michel, Viens, Patrice, Collette, Yves, Birnbaum, Daniel, Lopez, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445597/
https://www.ncbi.nlm.nih.gov/pubmed/23028451
http://dx.doi.org/10.1371/journal.pone.0043409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445597/
https://www.ncbi.nlm.nih.gov/pubmed/23028451
http://dx.doi.org/10.1371/journal.pone.0043409

Ejemplares similares